Diego Rossi

Dr. Diego Rossi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
DRDiego Rossi
Diego Rossi
Funda GokerFunda Goker
Funda Goker
FCFederico Angelo Cullati
Federico Angelo Cullati
ABAlessandro Baj
Alessandro Baj
DPDaniele Pignatelli
Daniele Pignatelli
Massimo Del FabbroMassimo Del Fabbro
Massimo Del Fabbro
Background: The treatment for severe OSAS includes maxillomandibular advancement surgical option in selected cases. The aim of this study was to evaluate the post-operative impact of bimaxillary surgery on satisfaction and consequently the quality of life of these patients. Methods: This study included 18 patients with severe OSAS who received maxillomandibular advancement surgery. Patients were divided into Group A (operated by CAD/CAM) and Group B (conventional surgery). The impact of bimaxillary surgery on satisfaction and quality of life of these patients was evaluated by utilizing post-operative life quality and Rustemeyer’s patient-satisfaction-based survey. Results: A total of 18 adult OSAS patients (Group A: 11 patients, Group B: 7 patients) with a mean age of 44.39 years (SD ± 9.43) were included. Mean follow-up period was 32.64 months (SD ± 21.91). No intra-operative complications were seen in any patients. Post-operative complication was seen in one patient and the mandible did not integrate. According to the results, overall post-operative satisfaction score was 79.72% (SD ± 9.96). There was no significant difference among those in Group A and Group B. Conclusions: Maxillomandibular advancement surgery seems to be beneficial in terms of patients’ satisfaction in severe adult OSAS patients and can be considered as a valuable option in selected cases.

1 January 2022
Verified
Journal Article
Closed access
FGF. Goker
F. Goker
CMC. Mazzucato
C. Mazzucato
MMM. Maggioni
M. Maggioni
ABA. Baj
A. Baj
AGA. B. Gianni
A. B. Gianni
MFM. Del Fabbro
M. Del Fabbro

22 January 2025 in Medicina
Verified
Journal Article
Open access
PDF file
ESEleonora Segna
Eleonora Segna
Funda GokerFunda Goker
Funda Goker
GTGiulia Tirelli
Giulia Tirelli
Massimo Del FabbroMassimo Del Fabbro
Massimo Del Fabbro
AGAldo Bruno Giannì
Aldo Bruno Giannì
DRDiego Rossi
Diego Rossi
Background and Objectives: Obstructive sleep apnea is an extremely diffuse pathology that, if left untreated, can lead to very serious cardiovascular consequences. The primary goal of treatment is to maintain airflow in the upper airway tract, which can be obtained thanks to orthognathic surgery such as maxillo-mandibular advancement (MMA). This procedure increases the volume of the posterior airway space (PAS)—a parameter considered fundamental in OSA physiology. However, the correlation between the degree of advancement, the volume increase, and the clinical improvement in OSA is not yet clear, even in patients who undergo virtual surgical planning. Aiming to test the correlation of these parameters and the role of PAS volume changes, we present our pre- and post-operative volumetric analysis of the PAS using cone beam computed tomography (CBCT) following CAD/CAM-assisted maxillomandibular advancement. Materials and Methods: We collected information from patients who underwent MMA for moderate or severe OSA, planned virtually with custom-made devices, between 2020 and 2022 at the Maxillofacial Surgery and Odontostomatology Unit of the Policlinico Hospital in Milan. The degree of mandibular advancement (pogonion antero-posterior advancement) was noted. All patients underwent pre- and post-operative CBCT and pre- and post-operative polysomnography to measure the Apnea–Hypopnea Index (AHI) parameters. Both exams were performed within six months before and after surgery. The surgeries were planned virtually along with the production of custom-made devices (cutting guides and mandibular osteosynthesis plates). Volumetric analysis of the PAS was performed pre- and post-CBCT images using medical segmentation software (Mimics, Materialise, Mimcs 26.0). Results: Ten patients (nine men and one woman) with a mean age of 51 years were included in this study. The mean pogonion advancement was 14.5 mm, ranging from 13.8 to 15.6. The mean pre-surgical AHI was 52.31 events/h, while the mean post-surgical AHI was 5.94 events/h (SD 5.34). The improvement in AHI was statistically significant (Wilcoxon matched-pairs signed-rank test, p value 0.004). The mean pre-surgical PAS volume was 8933 mm3, while the mean post-surgical volume was 10,609 mm3. In 8 out of 10 patients, the volume increased, with a mean increase of 2640 mm3 (max. 5183, min. 951), corresponding to a percentage increase variation ranging from 78% to 6%. In two patients, the volume decreased by 1591 (−16%) and 2767 mm3 (−31%), respectively. The difference between pre- and post-operative results was not statistically significant (paired t-test, p value 0.033). Conclusions: The results obtained confirm the efficacy of virtually planned MMA performed with custom-made devices in OSA therapy. However, they also show that PAS volume should not be used as a comprehensive parameter for OSA treatment evaluation because it does not always have a positive correlation with advancement and AHI.

1 January 2022
Verified
Journal Article
Closed access
DRDiego Rossi
Diego Rossi
FGF. Goker
F. Goker
FCF. Cullati
F. Cullati
ABA. Baj
A. Baj
DPD. Pignatelli
D. Pignatelli
MFM. Del Fabbro
M. Del Fabbro

1 May 2015 in Endocrine Abstracts
Verified
Journal Article
Open access
ECElisa Cairoli
Elisa Cairoli
CVCristina Eller Vainicher
Cristina Eller Vainicher
DRDiego Rossi
Diego Rossi
GBGiada Anna Beltramini
Giada Anna Beltramini
ARAntonio Russillo
Antonio Russillo
Iacopo ChiodiniIacopo Chiodini
Iacopo Chiodini
We report on the clinical and biochemical outcomes in a 20-year-old male suffering from active craniofacial monostotic fibrous dysplasia (MFD) treated with the RANK-L inhibitor, Denosumab, following unsatisfactory responses to prior long-term bisphosphonates therapy. The patient had been treated over 9 years with pamidronate (cumulative dose of 81 mg), but experienced only mild reductions in pain scores. Following initiation of Denosumab 60 mg subcutaneously, bone pain and bone turnover markers (osteocalcin, total and bone alkaline phosphatase and β-crosslaps) were monitored over a period of 14 months. Following the first administration, the patient demonstrated a promptly and pronounced clinical and biochemical response: within few hours the patient reported pain disappearance and after 4 weeks bone turnover markers fell to levels within the normal range. Three months after initiation of Denosumab the patient reported an acute pain reactivation that required a second administration. As previously, after few hours the pain disappeared. Later Denosumab was administered according to pain reappearance and the injections were always followed by complete pain relief. However, a gradual shortening of the pain-free interval between administrations was observed, ranging from 90 days after the first one to 75 days after the fifth one. Treatment with Denosumab was always well tolerated. The monitoring of bone turnover showed that all markers stayed in the lower half of the normal range, even at the moment of pain reappearance, suggesting that the effect of Denosumab on pain depends on mechanisms other than bone resorption suppression. In conclusion, Denosumab appears to be effective in reducing bone turnover and bone pain in adult patients with active MFD and could represent a good alternative to bisphosphonates, allowing to avoid elevate cumulative doses of these agents. Further studies are required to clarify the efficacy, safety and mechanisms of long-term therapeutic RANK-L inhibition in MFD.

1 December 2022 in Advances in Oral and Maxillofacial Surgery
Verified
Journal Article
Open access
DRDiego Rossi
Diego Rossi
DCDaniele Cantarella
Daniele Cantarella
LKLorena Karanxha
Lorena Karanxha
EMEvangelista Giovanni Mancini
Evangelista Giovanni Mancini
FCFederico Cullati
Federico Cullati
WMWon Moon
Won Moon